H. Debiec, J. Nauta, F. Coulet, M. Van-der-burg, V. Guigonis et al., Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies, The Lancet, vol.364, issue.9441, pp.1252-1259, 2004.
DOI : 10.1016/S0140-6736(04)17142-0

B. Hudson, The Molecular Basis of Goodpasture and Alport Syndromes: Beacons for the Discovery of the Collagen IV Family, Journal of the American Society of Nephrology, vol.15, issue.10, pp.2514-2527, 2004.
DOI : 10.1097/01.ASN.0000141462.00630.76

J. Patrakka, V. Ruotsalainen, P. Reponen, E. Qvist, J. Laine et al., RECURRENCE OF NEPHROTIC SYNDROME IN KIDNEY GRAFTS OF PATIENTS WITH CONGENITAL NEPHROTIC SYNDROME OF THE FINNISH TYPE, Transplantation, vol.73, issue.3, pp.394-403, 2002.
DOI : 10.1097/00007890-200202150-00013

S. Richards, Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders, Clinical and Applied Immunology Reviews, vol.2, issue.4-5, pp.241-253, 2002.
DOI : 10.1016/S1529-1049(02)00049-1

D. Brooks, Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models, Molecular Genetics and Metabolism, vol.68, issue.2, pp.268-275, 1999.
DOI : 10.1006/mgme.1999.2894

E. Koren and L. Zuckerman, Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction, Current Pharmaceutical Biotechnology, vol.3, issue.4, pp.349-360, 2002.
DOI : 10.2174/1389201023378175

T. Hunley, D. Corzo, M. Dudek, P. Kishnani, A. Amalfitano et al., Nephrotic Syndrome Complicating ??-Glucosidase Replacement Therapy for Pompe Disease, PEDIATRICS, vol.114, issue.4, pp.532-535, 2004.
DOI : 10.1542/peds.2003-0988-L

B. Winchester, A. Vellodi, and E. Young, The molecular basis of lysosomal storage diseases and their treatment, Biochemical Society Transactions, vol.28, issue.2, pp.150-154, 2000.
DOI : 10.1042/bst0280150

F. Dixon, J. Feldman, and J. Vazquez, EXPERIMENTAL GLOMERULONEPHRITIS: THE PATHOGENESIS OF A LABORATORY MODEL RESEMBLING THE SPECTRUM OF HUMAN GLOMERULONEPHRITIS, Journal of Experimental Medicine, vol.113, issue.5, pp.899-920, 1961.
DOI : 10.1084/jem.113.5.899

R. Glassock, Human Idiopathic Membranous Nephropathy ??? A Mystery Solved?, New England Journal of Medicine, vol.361, issue.1, pp.81-83, 2009.
DOI : 10.1056/NEJMe0903343

P. Ronco and H. Debiec, Pathogenesis of membranous nephropathy: recent advances and future challenges, Nature Reviews Nephrology, vol.181, issue.4, pp.203-213
DOI : 10.1007/s00467-006-0203-6
URL : https://hal.archives-ouvertes.fr/inserm-00919135

L. Beck, . Jr, R. Bonegio, G. Lambeau, D. Beck et al., Receptor as Target Antigen in Idiopathic Membranous Nephropathy, New England Journal of Medicine, vol.361, issue.1, pp.11-21, 2009.
DOI : 10.1056/NEJMoa0810457
URL : https://hal.archives-ouvertes.fr/hal-00417718

H. Debiec, F. Lefeu, M. Kemper, P. Niaudet, G. Deschênes et al., Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin, New England Journal of Medicine, vol.364, issue.22, pp.2101-2110, 2011.
DOI : 10.1056/NEJMoa1013792

P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E. Teles et al., Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study, The Journal of Pediatrics, vol.148, issue.4, pp.533-539, 2006.
DOI : 10.1016/j.jpeds.2005.12.014

C. Hendriksz, R. Giugliani, P. Harmatz, C. Lampe, A. Martins et al., Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP), Journal of Inherited Metabolic Disease, vol.10, issue.Suppl 1, pp.373-384, 2013.
DOI : 10.1007/s10545-011-9410-9

L. Giardino, S. Armelloni, A. Corbelli, D. Mattinzoli, C. Zennaro et al., Podocyte Glutamatergic Signaling Contributes to the Function of the Glomerular Filtration Barrier, Journal of the American Society of Nephrology, vol.20, issue.9, pp.1929-1940, 2009.
DOI : 10.1681/ASN.2008121286

T. Namba, T. Ishii, M. Ikeda, T. Hisano, T. Itoh et al., Inhibition of the human intermediate conductance Ca2+-activated K+ channel, hIK1, by volatile anesthetics, European Journal of Pharmacology, vol.395, issue.2, pp.95-101, 2000.
DOI : 10.1016/S0014-2999(00)00254-5

M. Morton, K. Hutchinson, P. Mathieson, I. Witherden, M. Saleem et al., Human Podocytes Possess a Stretch-Sensitive, Ca2+-Activated K+ Channel: Potential Implications for the Control of Glomerular Filtration, Journal of the American Society of Nephrology, vol.15, issue.12, pp.2981-2987, 2004.
DOI : 10.1097/01.ASN.0000145046.24268.0D

P. Kishnani, M. Nicolino, T. Voit, R. Rogers, A. Tsai et al., Chinese hamster ovary cell-derived recombinant human acid ??-glucosidase in infantile-onset Pompe disease, The Journal of Pediatrics, vol.149, issue.1, pp.89-97, 2006.
DOI : 10.1016/j.jpeds.2006.02.035

M. Rosenberg, W. Kingma, M. Fitzpatrick, and S. Richards, Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration, Blood, vol.93, pp.2081-2088, 1999.

J. Wang, J. Lozier, G. Johnson, S. Kirshner, D. Verthelyi et al., Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment, Nature Biotechnology, vol.268, issue.8, pp.901-908, 2008.
DOI : 10.1080/080352502760148621

H. Debiec, M. Hanoy, A. Francois, D. Guerrot, S. Ferlicot et al., Recurrent Membranous Nephropathy in an Allograft Caused by IgG3?? Targeting the PLA2 Receptor, Journal of the American Society of Nephrology, vol.23, issue.12, pp.1949-1954
DOI : 10.1681/ASN.2012060577
URL : https://hal.archives-ouvertes.fr/inserm-00919065